Catalent

Catalent to acquire Cook Pharmica for $950M

Tuesday, September 19, 2017

Catalent, a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has reached an agreement to acquire Bloomington, Indiana-based Cook Pharmica, an integrated provider of drug substance and drug product manufacturing and related services. The purchase price is $950 million, with $750 million to be paid at closing and the balance to be paid in equal installments, without interest, on each of the next four anniversaries of the closing. The acquisition will strengthen Catalent’s position as a leader in the rapidly growing area of biologics development and analytical services, manufacturing, and finished product supply.

[Read More]

Assessing the strategic impact of supply chain management

Thursday, June 15, 2017

The globalization of clinical trials and more complex protocols, which include adaptive designs and those for targeted therapies, have driven the need for new practices and strategies to reduce waste and inefficiencies in the clinical supply logistics area.

[Read More]

Catalent to acquire Pharmatek

Thursday, September 15, 2016

Catalent, a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has announced an agreement for Catalent, through its wholly owned subsidiary, Catalent Pharma Solutions, to acquire Pharmatek Laboratories, a West Coast, U.S.-based specialist in drug development and clinical manufacturing.

[Read More]

Catalent Biologics, Zumutor collaborate to enhanced antibodies

Thursday, August 11, 2016

Catalent Pharma Solutions, a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Zumutor Biologics, a developer of biosimilars, novel biobetters and New Biological Entities, have announced a successful research study, combining Catalent’s proprietary GPEx technology and Zumutor’s fucose knockout platform, to create new and more efficacious antibodies.

[Read More]

Catalent launches Quality, Product Development & Regulatory Affairs organization

Thursday, March 19, 2015

Catalent Pharma Solutions, a Somerset, N.J.-based global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has formed the Quality, Product Development & Regulatory Affairs organization, established to build upon Catalent’s experience in new product development, regulatory excellence, reliable supply and quality. Sharon Johnson, senior vice president, global quality & regulatory affairs, will head up Catalent’s new organization.

[Read More]

Catalent, Valerion collaborate on orphan genetic disorder treatments

Thursday, December 4, 2014

Catalent Pharma Solutions, a Somerset, N.J.-based global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, is collaborating with Valerion Therapeutics, a Concord, Mass.-based emerging science-driven company focused on the development of bio-therapeutics for orphan genetic diseases, to develop Valerion’s two lead product candidates.

[Read More]

Catalent, Cingulate Therapeutics ink agreement for new ADHD treatments

Tuesday, September 30, 2014

Catalent Pharma Solutions, headquartered in Somerset, N.J., has reached an exclusive development and licensing agreement with Cingulate Therapeutics (CTx), a Morristown, N.J.-based, privately held biopharmaceutical company, to support development of a series of new prescription pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) using Catalent’s OSDrC OptiDose drug delivery platform.

[Read More]